.

Deeper Knowledge, Faster

  • Anticipate your formulary budget
  • Uncover prior art in expired and abandoned patents
  • Drug patents and clinical trials in dozens of countries

► See Plans and Pricing

Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving 500+ biopharmaceutical companies globally:

Mallinckrodt
Julphar
QuintilesIMS
Covington
Johnson and Johnson
AstraZeneca
McKinsey
Colorcon
Harvard Business School
UBS

Generated: June 23, 2017

DrugPatentWatch Database Preview

Details for Patent: 9,216,179

« Back to Dashboard

Which drugs does patent 9,216,179 protect, and when does it expire?


Patent 9,216,179 protects ZURAMPIC and is included in one NDA.

This patent has five patent family members in four countries.

Summary for Patent: 9,216,179

Title:Treatment of gout and hyperuricemia
Abstract: Sodium 2-(5-bromo-4-(4-cyclopropylnaphthalen-1-yl)-4H-1,2,4-triazol-3-ylt- hio)acetate is described. In addition, pharmaceutical compositions and uses of such compositions for the treatment of a variety of diseases and conditions are described.
Inventor(s): Miner; Jeffrey (San Diego, CA), Girardet; Jean-Luc (San Diego, CA), Quart; Barry D. (Encinitas, CA)
Assignee: ARDEA BIOSCIENCES, INC. (San Diego, CA)
Application Number:13/704,192
Patent Claim Types:
see list of patent claims
Use;

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use
Ironwood Pharms Inc
ZURAMPIC
lesinurad
TABLET;ORAL207988-001Dec 22, 2015RXYesYes9,216,179► Subscribe COADMINISTERING WITH ALLOPURINOL TO REDUCE SERUM URIC ACID (SUA) BELOW 4 MG/DL; BELOW 6MG/DL IN PATIENTS HAVING URIC ACID DEPOSITS; AND/OR BELOW 6MG/DL WITH SUA INTRADAY CHANGE MORE THAN 50% AND/OR ADVERSE EVENT RATE LESS THAN 15%
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Foreign Priority and PCT Information for Patent: 9,216,179

PCT Information
PCT FiledJune 14, 2011PCT Application Number:PCT/US2011/040398
PCT Publication Date:December 22, 2011PCT Publication Number: WO2011/159732

International Patent Family for Patent: 9,216,179

Country Document Number Estimated Expiration Supplementary Protection Certificate SPC Country SPC Expiration
Canada2802407► Subscribe
European Patent Office2582683► Subscribe
Japan2013528650► Subscribe
Japan5964821► Subscribe
World Intellectual Property Organization (WIPO)2011159732► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

The estimated expiration dates shown above are derived by simply adding 20 years to the priority date.
Due to the complexity of determining patent expirations even in a single country, compounded by the diversity of global patent laws, it is advisable to have patent counsel verify freedom to operate.

Export unavailable in trial.
Subscribe for complete access.

For more information try a trial or see the database preview and plans and pricing

Serving 500+ biopharmaceutical companies globally:

Deloitte
Harvard Business School
Argus Health
US Army
Accenture
Medtronic
Teva
Chinese Patent Office
Federal Trade Commission
Mallinckrodt

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

Copyright 2002-2017 thinkBiotech LLC
ISSN: 2162-2639

Secure SSL Encrypted

Follow DrugPatentWatch:



Google
Twitter
Google Plus
botpot